EE621 Cost-Effectiveness Analysis of iGlarLixi Compared With Basal Bolus Insulin Regimen in Triple Metabolic Goal in Type 2 Diabetes Mellitus in Latin America

This study aims to calculate the achievement of the composite endpoints (CE) costs with iGlarLixi compared to Basal-Bolus (rapid-acting insulin plus Gla-U100 [B/B]) in 5 Latin-American countries: Panama, Costa Rica, Salvador, Guatemala, and Honduras.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. Londono, W. Garcia, C. Salamanca, L. Silva, V. Santos, A. Upegui Source Type: research